Literature DB >> 18434711

The effect of lipoproteins on the development and progression of renal disease.

Lorien S Dalrymple1, George A Kaysen.   

Abstract

The field of research examining how lipoproteins may contribute to the development and/or progression of renal disease has rapidly expanded over the last 25 years. In animal models, lipoproteins and lipids have been associated with both the initiation and progression of renal disease. Numerous potential mechanisms of lipoprotein-induced renal injury have been identified by utilizing animal models and tissue-culture experiments. However, with the exception of rare genetic mutations, the association between lipoproteins and human renal disease is less clear. In humans, the evidence that lipid-lowering therapy delays renal progression is limited. The purpose of this paper is to review the current literature on lipoprotein abnormalities and the development or progression of renal disease. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434711     DOI: 10.1159/000127980

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  20 in total

Review 1.  Clinical assessment and management of dyslipidemia in patients with chronic kidney disease.

Authors:  Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06-22       Impact factor: 2.801

Review 2.  Role of lipotoxicity in endothelial dysfunction.

Authors:  Jeong-a Kim; Monica Montagnani; Sruti Chandrasekran; Michael J Quon
Journal:  Heart Fail Clin       Date:  2012-08-10       Impact factor: 3.179

3.  Vitamin A deficiency results in dysregulation of lipid efflux pathway in rat kidney.

Authors:  Haiping Yang; Ke Chen; Xuan Zhang; Li Wang; Cuicui Li; Hong Tao; Lijia Wang; Qiu Li
Journal:  Pediatr Nephrol       Date:  2010-05-18       Impact factor: 3.714

4.  Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.

Authors:  Nosratola D Vaziri; Hyun Ju Kim; Hamid Moradi; Farbod Farmand; Kaveh Navab; Mohamad Navab; Susan Hama; Alan M Fogelman; Yasmir Quiroz; Bernardo Rodriguez-Iturbe
Journal:  Nephrol Dial Transplant       Date:  2010-05-20       Impact factor: 5.992

5.  Role of apolipoprotein E in renal damage protection.

Authors:  F Bonomini; L F Rodella; M Moghadasian; C Lonati; R Coleman; R Rezzani
Journal:  Histochem Cell Biol       Date:  2011-05-15       Impact factor: 4.304

Review 6.  Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials.

Authors:  Chi-Chih Hung; Jer-Chia Tsai; Hung-Tien Kuo; Jer-Ming Chang; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Rev Diabet Stud       Date:  2013-08-10

7.  Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency.

Authors:  Satoshi Takahashi; Keiju Hiromura; Mayuko Tsukida; Yuko Ohishi; Hiroko Hamatani; Noriyuki Sakurai; Toru Sakairi; Hidekazu Ikeuchi; Yoriaki Kaneko; Akito Maeshima; Takashi Kuroiwa; Hideaki Yokoo; Takeo Aoki; Michio Nagata; Yoshihisa Nojima
Journal:  J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 10.121

Review 8.  Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.

Authors:  George L Bakris
Journal:  Mayo Clin Proc       Date:  2011-05       Impact factor: 7.616

9.  Identification of modifiable chronic kidney disease risk factors by gender in an African-American metabolic syndrome cohort.

Authors:  Loretta Jackson Brown; Patricia C Clark; Karen A Armstrong; Zhao Liping; Sandra B Dunbar
Journal:  Nephrol Nurs J       Date:  2010 Mar-Apr       Impact factor: 0.959

10.  Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.

Authors:  Kyubok Jin; Keith Norris; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.